Medium 6.5Published Jun 23, 2026

CVE-2026-56402NanoClaw < 2.1.17 - Privilege Escalation via Unverified Approval Response Handler

Updated under an hour ago (Oct 27, 2026, 3:50 AM ET)

Does this affect you?

It affects nanocoai nanoclaw. Add what you run to find out whether that includes you.

No exploitation reported and no EPSS estimate yet.

Do this next

Start free and add your stack

Free account, 1 product

Every CVE for nanocoai nanoclaw

Exploited in the last 30 days

NanoClaw before 2.1.17 contains a privilege escalation vulnerability in the handleApprovalsResponse function that fails to verify responder role authorization. Attackers with a valid questionId can approve or reject privileged actions like package installation by submitting approval response payloads without proper role validation.

CVSS: 6.5 MEDIUM (v3.1, CNA)CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:N/I:H/A:N
Weakness (CWE): CWE-862
Known exploited: Not in CISA's KEV catalog
EPSS (exploitation in the next 30 days): Not loaded for this CVE
Assigned by: VulnCheck
NVD analysis: Deferred
Record last updated: Sep 17, 2026
First seen by InfoSec Signals: Oct 9, 2026

Affected products

Affected products

nanocoai nanoclaw nanocoai:nanoclaw (from the name)	before 2.1.17; 2.1.17 not affected	CNA record

References

References

https://github.com/nanocoai/nanoclaw/pull/2478	issue-tracking, patch
https://github.com/nanocoai/nanoclaw/commit/6227bd1a5b016fb1eb76411bb6681b4c924a51a0	patch
https://www.vulncheck.com/advisories/nanoclaw-privilege-escalation-via-unverified-approval-response-handler	third-party-advisory

The CVE record on cve.org NVD's entry

The CVE record is authoritative. Products marked “from the name” were identified from the CNA's free-text names, not a CPE, and are matched less certainly. This product uses the NVD API but is not endorsed or certified by the NVD.